Skip to main content
Johnson & Johnson
Healthcare · Drug Manufacturers - General
Made on Jul 30, 2026
Price at call $265.53
6-month call Neutral -4.3%
Target by Jan 2027 $254.00
Great value below $210.00
Model v0.6.0

Projection vs Actual (6M history + forecast)

The masterbrain's trajectory (blue, curved through its 7 checkpoints), the deterministic v0.3 control (dashed), and the actual price (green) overlaid from the prediction date forward.
Forecast Change -4.3% to $254.00
Predicted High $264.20 in 2 weeks
Predicted Low $254.00 at 6 months
Max Drawdown (predicted) -4.3%

Forecast

The masterbrain trajectory — 7 dated checkpoints. Short rungs (2w, 1m) show the typical range as the primary claim; point calls run from 2 months out. Every claim still gets graded. Predicted Jul 30, 2026 1:12 am
Neutral JNJ trends range-bound to $254.00 (-4.3% from $265.53) by Jan 2027. decay
ThesisJNJ trades well above composite fair value ($171-179) but its defensive profile, quality score, and earnings consistency support price stickiness. Expect mild drift lower as valuation gravity slowly asserts itself in a stress regime, though the low beta cushions downside. No near-term earnings catalyst to force a repricing.
Invalidated ifA break above $280 on positive pharma catalyst, or a break below $245 signaling valuation compression has begun in earnest.
Checkpointtime after the call Datewhen it gets graded Predictedthe claim: closing price Current priceactual close — fills in over time Predicted returnpredicted vs $265.53 at call Conv.brain's confidence, 1–10 Driverwhy the brain put the point here
Prediction made Jul 30, 2026 $265.53 at call The anchor — every point below is measured from this price and date.
2 weeks Aug 13, 2026 $252.79–$278.27 typical range · internal point $264.20 ±4.8% 7/10 Low-beta defensive holds in stress tape near-term
What actually happened: closed $260.86 on Aug 12, 2026 = -1.8% vs the call (predicted -0.5%)  ·  direction HIT (called flat, was flat)  ·  off by 1.3 pp  ·  accuracy 10/10  ·  typical range ±4.8%: inside the band  ·  S&P +4.2% over the same window — beat it
1 month Aug 30, 2026 $247.07–$283.99 typical range · internal point $263.00 ±7.0% 6/10 Mild drift as talc headline weighs modestly
2 months Sep 30, 2026 $261.50 -1.5% 5/10 Q3 print approaches with no calendar catalyst yet
3 months Oct 30, 2026 $259.00 -2.5% 5/10 Valuation gravity begins nudging toward fair value
4 months Nov 30, 2026 $257.50 -3.0% 4/10 Year-end positioning; defensive bid partially offsets
5 months Dec 30, 2026 $256.00 -3.6% 4/10 Tax-loss avoided on winner, holds up
6 months Jan 30, 2027 $254.00 -4.3% 4/10 Drift toward deterministic baseline as sentiment stale

Why ranges on the short rungs? A 102-prediction trial (2026-07-21) showed 2-week point calls carry no information here — three prompt formulations all lost to simply predicting zero — while the stock's own volatility scale (σ×√t) described those windows well. So the short rungs claim what's actually knowable: the typical travel, with earnings timing flagged where the variance will come from. The internal point calls keep being generated and graded to map where real skill begins. Full evidence: stocks/predictions/V0.5-DESIGN.md §8.

Deterministic control (v0.3 value line) targets $254.51 (-4.1%) — both lines get graded at every checkpoint, so the brain has to beat the formula, not just replace it. Brain: claude-opus-4-7.

Weaknesses

0 blocking · 0 degraded · 2 notes — follow the chain top-down (cause → effect).
  • Note
    Valuation anchor absent: dcf.
    anchor:dcf
  • Note
    Valuation anchor absent: anchored_pe.
    anchor:anchored_pe

Equation Inputs

Everything feeding the v0.6.0 model — value anchors, the stock's own price behaviour, and the tunable knobs.

Value anchors (from deep analysis)

Price at call$265.53
Composite fair value$171.51
Signal-adjusted fair value$179.40
DCF fair value
Anchored-PE fair value
Buy-below (value lens)$210.00
Value net score-79
Value confidence6 / 10
Quality net score+100
Memo confidence8 / 10
Deserved value (base)
Quality tilt
Deserved value (used)
Coherence (value × quality)

Price behaviour (trailing — shapes the realism line)

Realized volatility (annualized) 1m 26.2%  3m 24.1%  6m 20.6%  
Daily σ (realism noise)1.5%
Beta vs S&P 500 1m -0.96  3m -0.52  5m -0.17  
Trailing 6-month return18.3%

Knobs (equation params)

ladderArray
llm_modelclaude-opus-4-7
max_tokens3000
control_knobsArray
Neutral band (%)5
earnings_briefv1
prompt_versionp1
control_versionv0.3.0

Version & Tech Chain

What produced this prediction — stamped on the record so versions can be compared by success rate later.
Model v0.6.0 #271041f8fcd5

Tech composition (what this version is built from)

#ProcessKindGroup
1 Synthesis valuation-synthesis deterministic final
2 Scenario Analysis scenario-valuation deterministic valuation
3 Valuation / Mispricing ext-lens-value llm extended
4 Company Quality ext-lens-quality llm extended
5 Forensic Memo (combiner) ext-forensic-memo llm extended
6 Classification company-classification llm foundation
7 Live Quote fmp-quote data market-data

Inputs used (the runs that fed this prediction)

Upstream processRanLagRun id
company-classification Jul 30, 2026 freshest JNJ-20260730-001020-3519
ext-forensic-memo Jul 30, 2026 freshest ext-JNJ-20260730-005820-bf3b
ext-lens-quality Jul 30, 2026 freshest ext-JNJ-20260730-005820-bf3b
ext-lens-sentiment Jul 30, 2026 freshest ext-JNJ-20260730-005820-bf3b
ext-lens-value Jul 30, 2026 freshest ext-JNJ-20260730-005820-bf3b
scenario-valuation Jul 30, 2026 freshest JNJ-20260730-001020-3519
valuation-synthesis Jul 30, 2026 freshest JNJ-20260730-001020-3519

Inputs flagged 7d+ behind the freshest one may be stale relative to the rest of the analysis.

Saved History

2 frozen snapshots — the record we score once predictions mature.
MadeModelCallAt callTargetExp.Eval due
Jul 30, 2026 v0.6.0 Neutral $265.53 $254.00 -4.3% Jan 2027 viewing
Jun 23, 2026 v0.3.0 Neutral $231.29 $234.04 +1.2% Dec 2026 view

Not Yet Modeled

What this v0.6.0 forecast deliberately ignores — the work ahead, in plain sight.
  • Scenario probabilities — one path, no bull/bear split (base_prob = 1.0).
  • Intraday / sub-2-week behaviour — the first claim is at 14 days by design (EOD product).
  • Position sizing / portfolio context — the path is a price claim only.